Tian Zhang, MD, MHS

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Pfizer, Eli Lilly, Tempus, ALX Oncology, Exelixis, Merck, OncoC4
    Topic:
    PI (research funding)
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Pfizer, MJH Associates, Vaniam, Aptitude Health, PeerView, Clinical Care Options, Mashup Media
    Topic:
    Consultant
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck, Exelixis, Sanofi-Aventis, Janssen, AstraZeneca, Pfizer, BMS, SeaGen, Eisai, Aveo Pharmaceuticals, Bayer, Eli Lilly, Novartis, Gilead, EMD Serono
    Topic:
    Advisory Board
    Date added:
    03/22/2022
    Date updated:
    04/11/2024
Return to 109 Division of Hem/Onc Solid Oncology Conference: "Early-Stage Bladder Cancer & Metastatic Bladder Cancer" (041824)